Why the study?
Does dual ANG2/VEGFR2 blockade suppress tumor revascularization and progression in tumors resistant to VEGFR2 blockade?
Population
Late-stage RIP1-Tag2 pancreatic neuroendocrine tumors and MMTV-PyMT mammary adenocarcinomas
Comparison
Dual ANG2/VEGFR2 blockade vs VEGFR2 inhibition alone
Design
Preclinical
Authors
Loading...
May warrant dual ANG2/VEGFR2 testing in resistant PNET models; leaves open clinical translation and tumor-type specificity.
Does dual ANG2/VEGFR2 blockade suppress tumor revascularization and progression in tumors resistant to VEGFR2 blockade?
Evasive tumor resistance to anti-VEGFA therapy may involve the adaptive enforcement of ANG2-TIE2 signaling, which can be reversed by ANG2 neutralization.
Rigamonti et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: